While the Phase I trial was not primarily designed to assess the efficacy of ATL1103, which will occur in larger and longer term clinical trials in patients, the results achieved on these parameters in this trial in normal subjects indicate that ATL1103 demonstrated the relevant pharmacological activity to support its further development as a potential treatment for acromegaly and other growth hormone and IGF-I related disorders which include diabetic eye and kidney complications and certain forms of cancer
ANP Price at posting:
32.0¢ Sentiment: None Disclosure: Not Held
